natgillin/translations-raw huggingface dataset:
Passion flower is the common name for the above-ground parts of the plant Passiflora incarnata L. The HMPC conclusions only cover passion flower preparations which are obtained by comminuting (reducing into tiny pieces) or powdering the dried above-ground parts or as dry and liquid extracts. 
Taimsete ravimite komitee järeldused käsitlevad üksnes kannatuslilleürdi valmistisi, mis saadakse maapealsete osade kuivatamisel ja peenestamisel (väikesteks osadeks jahvatamisel) või pulbristamisel või mis esinevad kuiv- või märgekstraktidena.
In its assessment, the HMPC also considered published clinical studies of passion flower medicines. 
Taimsete ravimite komitee uuris hinnangu andmisel ka kannatuslilleürti sisaldavate ravimite avaldatud kliinilisi uuringuid.
Therefore, the HMPC conclusions on the use of passion flower medicines are based on their long-standing use. 
Seetõttu põhineb taimsete ravimite komitee järeldus kannatuslilleürti sisaldavate ravimite kasutamise kohta nende pikaajalisel kasutamisel.
To obtain a dry extract the solvent is then evaporated. 
Seejärel lahusti aurustatakse, et järele jääks kuivekstrakt.
The main measure of effectiveness was the response to treatment after 16 weeks. 
Efektiivsuse põhinäitaja oli ravivastus 16 nädala järel.
Further information of Targretin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Lisateave Targretini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Targretin? 
Mis meetmed võetakse, et tagada Targretini ohutu ja efektiivne kasutamine?
The response rates according to the 5 skin scores were 36% and 27%, respectively. 
Ravivastus 5 skoori alusel oli vastavalt 36% ja 27%.
Targretin was not compared with another medicine. 
Targretini ei võrreldud teiste ravimitega.
Treatment should continue as long as the patient benefits from it. 
Ravi tuleb jätkata seni, kuni see on patsiendile kasulik.
Targretin (bexarotene) EMA/234177/2018 
Targretin (beksaroteen) EMA/234177/2018
Targretin received a marketing authorisation valid throughout the EU on 29 March 2001. 
Targretini müügiluba, mis kehtib kogu ELis, anti 29. märtsil 2001.
Targretin (bexarotene) 
Targretin (beksaroteen)
Other information about Targretin 
Muu teave Targretini kohta
Targretin is available as capsules (75 mg). 
Targretini turustatakse kapslitena (75 mg).
As for all medicines, data on the use of Targretin are continuously monitored. 
Nagu kõigi ravimite puhul, teostatakse Targretini kasutamise kohta pidevat järelevalvet.
The dose is adjusted depending on the patient's response to treatment or side effects. 
Annust kohandatakse vastavalt patsiendi ravivastusele või kõrvalnähtudele.
Side effects reported with Targretin are carefully evaluated and any necessary action taken to protect patients. 
Targretini kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Targretin have been included in the summary of product characteristics and the package leaflet. 
Targretini ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
What is Targretin and what is it used for? 
Mis on Targretin ja milleks seda kasutatakse?
Targretin must not be used in women who are pregnant or breast-feeding, or women who could become pregnant and who are not using effective contraception; patients who have had pancreatitis (inflammation of the pancreas); patients with uncontrolled hypercholesterolaemia (high blood cholesterol), hypertriglyceridaemia (high blood triglycerides [fat]) or thyroid disease; patients with hypervitaminosis A (high levels of vitamin A); patients with liver disease; patients with an ongoing body infection. 
Targretini ei tohi kasutada rasedad, imetavad naised ega rasestumisvõimelised naised, kes ei kasuta efektiivseid rasestumisvastaseid vahendeid; patsiendid, kellel on olnud pankreatiit (kõhunäärmepõletik); ravile mittealluva hüperkolesteroleemia (vere suur kolesteroolisisaldus), hüpertriglütserideemia (vere suur triglütseriidide (teatud rasvade) sisaldus) või kilpnäärmehaigusega patsiendid; A-hüpervitaminoosiga (suur A-vitamiini sisaldus) patsiendid; maksahaigusega patsiendid; süsteemse infektsiooniga (nakkusega) patsiendid.
For more information about using Targretin, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Targretini kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
The effectiveness of Targretin has been examined in two studies involving a total of 193 patients with CTCL who received at least two previous treatments. 
Targretini efektiivsust uuriti kahes uuringus, milles osales kokku 193 naha T-rakklümfoomiga patsienti, kes olid varem saanud ravi vähemalt kahel korral.
The Agency recommended that Targretin be given marketing authorisation. 
Amet soovitas anda ravimile Targretin müügiloa.
The recommended starting dose is 300 mg/m2/day, taken as a single dose once a day with a meal. 
Soovitatav algannus on 300 mg/m2 ööpäevas ühekordse annusena koos söögiga.
Targretin is used in patients who have an advanced disease and have had at least one other treatment. 
Targretini kasutatakse patsientidel, kelle haigus on kaugelearenenud ja kes on saanud vähemalt üht muud ravi.
Ninety-three of these patients had advanced disease that had not responded to other treatment. 
Uuringus oli 93 patsiendil haigus kaugelearenenud, mis ei allunud muule ravile.
Sixty-one patients were treated at the starting dose of 300 mg/m2/day. 
61 patsienti raviti algannusega 300 mg/m2 ööpäevas.
The dose of Targretin is based on the patient's body surface area in square metres (m2). 
Targretini annus määratakse vastavalt patsiendi kehapindalale ruutmeetrites (m2).
What are the risks associated with Targretin? 
Mis riskid Targretiniga kaasnevad?
How does Targretin work? 
Kuidas Targretin toimib?
The most common side effects with Targretin (which may affect more than 1 patient in 10) are leucopenia (reduced white cell count), hypothyroidism (underactive thyroid gland), hyperlipaemia (high levels of fats in the blood), hypercholesterolaemia (high blood cholesterol), exfoliative dermatitis (skin peeling), pruritus (itching), rash, pain, headache and weakness. 
Targretini kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on leukopeenia (leukotsüütide ehk vere valgeliblede vähesus), hüpotüreoos (kilpnäärme alatalitlus), hüperlipideemia (vere suur rasvasisaldus), hüperkolesteroleemia (vere suur kolesteroolisisaldus), eksfoliatiivne dermatiit (teatud nahaketendus), pruriit (kihelus), lööve, valu, peavalu ja nõrkus.
The European Medicines Agency decided that Targretin's benefits are greater than its risks for the treatment of the skin manifestations of advanced-stage CTCL patients refractory to at least one treatment. 
Euroopa Ravimiamet otsustas, et Targretini kasulikkus naha kaugelearenenud T-rakklümfoomi nahanähtude ravis patsientidel, kelle haigus ei ole allunud vähemalt ühele ravile, on suurem kui sellega kaasnevad riskid.
Across the two studies, among the patients who received 300 mg/m2, about half of them responded to treatment, according the doctor's grading. 
Mõlemas uuringus kokku tekkis arsti hinnangu alusel ravivastus ligikaudu pooltel patsientidest, kes kasutasid ravimit annuses 300 mg/m2.
For the full list of side effects reported with Targretin, see the package leaflet. 
Targretini kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
grading of improvement, as well as by a score of 5 clinical signs (area of skin affected, redness, raised areas, scale-like skin and colour). 
Seda mõõdeti selle järgi, kuidas arst hindas seisundi paranemist, ja 5 kliinilise nähu skoori alusel (nahakahjustuse pindala, punetus, kõrgenenud nahapiirkonnad, ketendus, värvus).
CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin. 
Naha Trakklümfoom on lümfoomi (lümfikoe vähk) harvaesinev vorm, mille korral kasvavad nahas T-rakud (teatud leukotsüüdid ehk vere valgelibled).
How is Targretin used? 
Kuidas Targretini kasutatakse?
What benefit of Targretin have been shown in studies? 
Milles seisneb uuringute põhjal Targretini kasulikkus?
Targretin is a cancer medicine used for the treatment of the visible signs on the skin of cutaneous Tcell lymphoma (CTCL). 
Targretin on vähiravim, mida kasutatakse naha T-rakklümfoomi nahanähtude raviks.
An overview of Targretin and why it is authorised in the EU 
Ülevaade ravimist Targretin ja ELis müügiloa väljastamise põhjendus
The active substance in Targretin, bexarotene, belongs to the group of retinoids, substances that are derived from vitamin A. The exact way bexarotene works in CTCL is not known. 
Targretini toimeaine beksaroteen kuulub retinoidide (A-vitamiinist saadud ained) rühma.
Targretin can only be obtained with a prescription and treatment should only be initiated and maintained by a doctor who has experience in the treatment of patients with CTCL. 
Ravi peab alustama ja jätkama naha T-rakklümfoomiga patsientide ravis kogenud arst.
Why is Targretin authorised in the EU? 
ELis Targretinile väljastatud müügiloa põhjendus
Levetiracetam Hospira levetiracetam 
Levetiracetam Hospira levetiratsetaam
A risk management plan has been developed to ensure that Levetiracetam Hospira is used as safely as possible. 
Töötati välja riskijuhtimiskava, et tagada Levetiracetam Hospira võimalikult ohutu kasutamine.
This is a type of epilepsy where too much electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one side of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear. 
See on epilepsia vorm, mille puhul aju ühe poolkera elektriline liigtalitlus tekitab selliseid sümptomeid nagu ühe kehapoole järsud tõmblused, kuulmis-, haistmis- või nägemishäired, tuimus või äkiline hirmutunne.
The full EPAR for Levetiracetam Hospira can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst ja riskijuhtimiskava kokkuvõte Levetiracetam Hospira kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Secondary generalisation occurs when the overactivity later reaches the whole brain. 
Sekundaarse generaliseerumise korral levib liigtalitlus edasi üle kogu aju.
The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Hospira on the 08 January 2014. 
Euroopa Komisjon andis Levetiracetam Hospira müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 08. jaanuaril 2014.
Levetiracetam Hospira infusion should only be used temporarily, while treatment by mouth is not feasible. 
Levetiracetam Hospira infusiooni tohib kasutada ainult ajutiselt, kui suukaudne ravi ei ole võimalik.
What measures are being taken to ensure the safe and effective use of Levetiracetam Hospira? 
Mis meetmed võetakse, et tagada Levetiracetam Hospira ohutu ja efektiivne kasutamine?
The Committee recommended that Levetiracetam Hospira be approved for use in the EU. 
Komitee soovitas Levetiracetam Hospira kasutamise Euroopa Liidus heaks kiita.
• primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause). 
• primaarselt generaliseerunud toonilis-kloonilised epilepsiaepisoodid (rasked epilepsiaepisoodid, millega kaasneb teadvusekaotus) vähemalt 12-aastastel patsientidel, kellel on idiopaatiline generaliseerunud epilepsia (epilepsia liik, mille tekkepõhjust peetakse geneetiliseks).
• partial-onset seizures with or without generalisation in patients from four years of age; 
• partsiaalsed epilepsiaepisoodid koos generaliseerumisega või ilma vähemalt 4-aastastel patsientidel;
Other information about Levetiracetam Hospira 
Muu teave Levetiracetam Hospira kohta
Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk. 
Seetõttu on inimravimite komitee arvamusel, et nagu ka Keppra korral, ületab ravimi kasulikkus sellega kaasnevad riskid.
No additional studies were needed as Levetiracetam Hospira is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Keppra. 
Lisauuringuid ei olnud vaja, sest Levetiracetam Hospira on infusioonina manustatav geneeriline ravim ja sisaldab sama toimeainet nagu võrdlusravim Keppra.
This helps Levetiracetam Hospira to stabilise electrical activity in the brain and prevent seizures. 
Valk aitab Levetiracetam Hospiral stabiliseerida aju elektrilist talitlust ja ennetada epilepsiaepisoode.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Levetiracetam Hospira has been shown to have comparable quality and to be bioequivalent to Keppra. 
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Levetiracetam Hospira võrreldav kvaliteet ja bioekvivalentsus ravimiga Keppra.
It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partialonset seizures (fits) with or without secondary generalisation. 
Seda tohib kasutada monoteraapiana äsja diagnoositud epilepsiaga vähemalt 16-aastastel patsientidel, et ravida partsiaalseid epilepsiaepisoode koos sekundaarse generaliseerumisega või ilma.
• myoclonic seizures (short, shock-like jerks of a muscle or a group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy; 
• müokloonilised epilepsiaepisoodid (lühiajalised šokitaolised lihaste või lihasrühmade tõmblused) vähemalt 12-aastastel patsientidel, kellel on juveniilne müoklooniline epilepsia;
Because Levetiracetam Hospira is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Et Levetiracetam Hospira on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
The company provided data from the published literature on levetiracetam. 
Ettevõte esitas levetiratsetaami kohta avaldatud kirjandusest pärinevad andmed.
What is Levetiracetam Hospira and what is it used for? 
Mis on Levetiracetam Hospira ja milleks seda kasutatakse
This means that Levetiracetam Hospira is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra. 
See tähendab, et Levetiracetam Hospira on sarnane võrdlusravimiga Keppra, millel juba on Euroopa Liidus müügiluba.
This is a summary of the European public assessment report (EPAR) for Levetiracetam Hospira. 
See on ravimi Levetiracetam Hospira Euroopa avaliku hindamisaruande kokkuvõte.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Levetiracetam Hospira, including the appropriate precautions to be followed by healthcare professionals and patients. 
Selle alusel lisati Levetiracetam Hospira omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
For practical information about using Levetiracetam Hospira, patients should read the package leaflet or contact their doctor or pharmacist. 
Kui vajate Levetiracetam Hospira kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
It is not intended to provide practical advice on how to use Levetiracetam Hospira. 
Hindamisaruandes ei anta Levetiracetam Hospira kasutamise praktilisi nõuandeid.
Why is Levetiracetam Hospira approved? 
Miks Levetiracetam Hospira heaks kiideti?
Levetiracetam Hospira can only be obtained with a prescription and is available as a concentrate (100 mg/ml) that is made up into a solution for infusion (drip) into a vein. 
Seda turustatakse kontsentraadina (100 mg/ml), millest saab valmistada infusioonilahuse (venoosseks tilkinfusiooniks).
Levetiracetam Hospira is a ‘generic medicine'. 
Levetiracetam Hospira on geneeriline ravim.
In patients aged between four and 17 years weighing less than 50 kg, the starting dose is 10 mg per kilogram body weight twice a day, which can be increased up to 30 mg/kg twice a day. 
4- kuni 17-aastastel patsientidel kehakaaluga alla 50 kg on algannus 10 mg kehakaalu kg kohta kaks korda ööpäevas.
For more information about treatment with Levetiracetam Hospira, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Levetiracetam Hospiraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
Levetiracetam Hospira can also be used as an add-on to other anti-epileptic medicines to treat: 
Levetiracetam Hospirat tohib kasutada ka teiste epilepsiaravimite täiendava ravimina, et ravida järgmisi seisundeid:
Lower doses are used in patients who have reduced kidney function. 
Väiksemaid annuseid kasutatakse neerupuudulikkusega patsientidel.
The exact way in which levetiracetam works is still unclear but it seems to interfere with a protein called synaptic vesicle protein 2A, which is found in the spaces between nerves and is involved in the release of chemical messengers from nerve cells. 
Levetiratsetaami täpne toimemehhanism ei ole veel teada, kuid see näib sekkuvat sünapsipõiekeste valgu 2A toimesse.
Levetiracetam Hospira is an anti-epileptic medicine that contains the active substance levetiracetam. 
Levetiracetam Hospira on epilepsiaravim, mis sisaldab toimeainet levetiratsetaami.
When Levetiracetam Hospira is added to another anti-epileptic treatment, the starting dose in patients over 12 years weighing 50 kg or more is 500 mg twice a day. 
Levetiracetam Hospira lisamisel muule epilepsiaravimile vähemalt 12-aastastel patsientidel kehakaaluga üle 50 kg on algannus 500 mg kaks korda ööpäevas.
How is Levetiracetam Hospira used? 
Kuidas Levetiracetam Hospirat kasutatakse?
The dose can be further increased at two-week intervals according to the patient's response, to a maximum dose of 1,500 mg twice a day. 
Olenevalt patsiendi ravivastusest tohib annust 2-nädalase vahega suurendada kuni maksimaalse annuseni 1500 mg kaks korda ööpäevas.
The active substance in Levetiracetam Hospira, levetiracetam, is an anti-epileptic medicine. 
Levetiracetam Hospira toimeaine levetiratsetaam on epilepsiaravim.
When Levetiracetam Hospira is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day. 
Levetiracetam Hospira kasutamisel monoteraapiana on algannus 250 mg kaks korda ööpäevas.
How does Levetiracetam Hospira work? 
Kuidas Levetiracetam Hospira toimib?
What are the benefits and risks of Levetiracetam Hospira? 
Milles seisneb Levetiracetam Hospira kasulikkus ja mis riskid ravimiga kaasnevad?
How has Levetiracetam Hospira been studied? 
Kuidas Levetiracetam Hospirat uuriti?
The medicine is used in: 
Ravimit kasutatakse:
Further information on Myalepta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Lisateave Myalepta kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What measures are being taken to ensure the safe and effective use of Myalepta? 
Mis meetmed võetakse, et tagada Myalepta ohutu ja efektiivne kasutamine?
Patients or carers can inject the medicine themselves once they have been trained. 
Patsiendid või hooldajad tohivad süstida ravimit ise, kui on saanud asjakohase väljaõppe.
Myalepta (metreleptin) 
Myalepta (metreleptiin)
The European Medicines Agency therefore decided that Myalepta's benefits are greater than its risks and it can be authorised for use in the EU. 
Euroopa Ravimiamet otsustas, et Myalepta kasulikkus on suurem kui sellega kaasnevad riskid, ja lubati ravimi kasutamine ELis.
In the studies Myalepta was not compared with any other treatment. 
Uuringutes ei võrreldud Myaleptat ühegi muu ravimiga.
What is Myalepta and what is it used for? 
Mis on Myalepta ja milleks seda kasutatakse?
As for all medicines, data on the use of Myalepta are continuously monitored. 
Nagu kõigi ravimite puhul, teostatakse ka Myalepta kasutamise kohta pidevat järelevalvet.
This is because it has not been possible to obtain complete information about Myalepta due to the rarity of the condition. 
See tähendab, et harvaesineva haiguse tõttu ei olnud võimalik saada Myalepta kohta täielikku teavet.
It also results in insulin resistance (when the body is unable to recognise insulin, a hormone that helps regulate blood sugar levels). 
Samuti põhjustab see insuliiniresistentsust (kui organism ei reageeri vere glükoosisisaldust reguleerida aitavale hormoonile insuliinile).
However, the medicine does not restore fat tissue under the skin. 
Samas ei taasta ravim nahaalust rasvkude.
After 12 months of treatment, blood levels of fats (triglycerides) decreased from around 15 mmol/l to around 5 mmol/l in patients with generalised disease, and from around 16 mmol/l to around 6 mmol/l in patients with partial disease. 
Pärast 12-kuulist ravi vähenes generaliseerunud haigusega patsientidel rasvade (triglütseriidide) sisaldus veres väärtuselt ligikaudu 15 mmol/l väärtuseni ligikaudu 5 mmol/l ja osalise haigusega patsientidel väärtuselt ligikaudu 16 mmol/l väärtuseni ligikaudu 6 mmol/l.
The recommended daily dose depends on the patient's bodyweight and is adjusted based on the patient's response to treatment. 
Soovitatav ööpäevane annus sõltub patsiendi kehakaalust ja annust kohandatakse patsiendi ravivastusega.
Insulin resistance was also improved: blood levels of a substance called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled, fell from 8.6% to 6.4% in patients with generalised lipodystrophy, and from 8.8% to 8.0% in patients with partial lipodystrophy. 
Samuti paranes insuliiniresistentsus: glükohemoglobiini (HbA1c) sisaldus veres, mis näitab vere glükoosisisalduse reguleeritavust, vähenes generaliseerunud lipodüstroofiaga patsientidel väärtuselt 8,6% väärtusele 6,4% ja osalise lipodüstroofiaga patsientidel väärtuselt 8,8% väärtusele 8,0%.
It replaces leptin and increases fat breakdown in the blood, muscles and liver, thereby correcting some abnormalities in patients with lipodystrophy, including insulin resistance. 
See asendab leptiini ja suurendab veres, lihastes ja maksas sisalduva rasva lagunemist, korrigeerides nii lipodüstroofiaga patsientidel teatud häireid, sealhulgas insuliiniresistentsust.
For more information about using Myalepta, see the package leaflet or contact your doctor or pharmacist. 
Lisateavet Myalepta kasutamise kohta vt pakendi infolehest või pöörduge oma arsti või apteekri poole.
Myalepta has been authorised under ‘exceptional circumstances'. 
Myalepta on saanud müügiloa erandlikel asjaoludel.
Since Myalepta has been authorised under exceptional circumstances, the company that markets Myalepta will set-up a registry of patients treated the medicine, and conduct studies to further investigate the benefits and risks of treatment including the possibility for Myalepta to trigger the production of antibodies. 
Et Myalepta on saanud müügiloa erandlikel asjaoludel, koostab Myalepta turustaja ravimiga ravitud patsientide registri ja korraldab uuringud, et täiendavalt uurida ravimi kasulikkust ja riske, sealhulgas võimalust, et Myalepta vallandab antikehade tekke.
The most common side effects with Myalepta (which may affect more than 1 in 10 people) are hypoglycaemia (low blood glucose) and weight loss. 
Myalepta kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on hüpoglükeemia (vere väike glükoosisisaldus) ja kehakaalu vähenemine.